Medical Device News Magazine

Vascular Surgeon in Ireland Views: The COVID-19 Cytokine Storm & the Novel Truth

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Based on observations in the USA, Spain, Italy, France, and the UK, and from postmortem of lung involvement in COVID 19, all revealed pulmonary thrombosis, which is not typical ARDS. More alarming, was that patient hypoxemia was not responding to PEEP but high oxygen flow[1].

A Chinese scientist[2]  described the hypothesis of COVID 19, as methemoglobin, where COVID 19 virus structural protein, sticks to heme – displaces oxygen – which alters the iron-free ion, that leads to inflammation of alveolar macrophages which culminate to the systemic response ending in a cytokine storm. They suggested that free radical’s scavengers and iron-chelating agents if are added to the protocol of management might ameliorate the inflammatory response.

COVID 19, SARS2 is not ‘pneumonia’ nor ARDS. Invasive ventilation is the last resort, as emergency intubation from the Chinese, Italian and American experience had higher mortality, not to mention complications from tracheal scarring and stiff lung during the duration of intubation.  Furthermore, a new treatment protocol needs to be established in order to control the prolonged and progressive hypoxia of COVID191.

People are desaturating due to the failure of the blood to carry oxygen. This will lead to multi-organ failure and high mortality. The lung damage seen on CT scans is due to the oxidative stress released from the hemolysis red blood cells, which in turn overwhelm the natural defenses against pulmonary oxidative stress and cause Cytokine storm. There is always-bilateral ground-glass opacity in the lungs. Recurrent admission for post-hypoxic leukoencephalopathy fortifies the findings of the Italians, Spanish, and Americans3 that COVID-19 patients are suffering from metabolic hypoxia due to blood capacity failure.

The Chinese hypothesis2 that had been publicized that the following cascade might explain the vicious circle theoretically that the patient goes through

1) Without the iron ion, hemoglobin can no longer bind to oxygen. Once the hemoglobin is impaired, the red blood cell is essentially none functioning in carrying and delivering oxygen to any tissues. This leads to the destruction of the red blood cells and the patient’s oxygen saturation levels drop significantly.

COVID 19 patients, unlike CO poisoning in which eventually the CO can break off, the affected hemoglobin is permanently stripped of its ability to carry oxygen where the body compensates by secreting excess erythropoietin to stimulate the bone marrow to secrete new red blood cells.


References:

[1] https://time.com/5818547/ventilators-coronavirus/

[1] COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism Wenzhong Liu 1,2,*, Hualan Li2

#INVESTIGATIONALJOURNALISM #WHO #COVID19 #Cytokine

Please feel free to comment on this opinion.  The comment field can be found at the bottom of the page. 

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”